To further examine the therapeutic potentials of our CAR-T cells in vivo, we utilized mouse xenograft tumor models of CEACAM5-expressing DM4S (A549-CEACAM5), DM4R (H1975-CEACAM5) and CEACAM5-negative DM4S (A549) NSCLCs. Here, CEACAM5 is linked to neoplasm.